Treating hepatitis C virus in HIV patients: Are side effects a real obstacle?

AIDS Reviews

Volumn 9, Issue 1, 2007, Pages 16-24

  Gatti, Francesca ^a,b   Nasta, Paola ^a   Matti, Alessandro ^a   Manno, Daniela ^a   Mendeni, Monia ^a   Puoti, Massimo ^a   Carosi, Giampiero ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Divisione di Malattie Infettive   (Italy)

Author keywords

HCV HIV coinfection; Interferon; Ribavirin; Side effects

Indexed keywords

ADENOSINE; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; CITALOPRAM; COTRIMOXAZOLE; DIDANOSINE; ESCITALOPRAM; GANCICLOVIR; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 11; RIBAMIDINE; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ALOPECIA; ANEMIA; ASTHENIA; BLOOD TOXICITY; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DEPRESSION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATTY LIVER; FLU LIKE SYNDROME; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; LACTIC ACIDOSIS; LEUKOPENIA; LIVER FAILURE; LOW DRUG DOSE; MENTAL DISEASE; MITOCHONDRIAL TOXICITY; MONOTHERAPY; MYALGIA; NEUTROPENIA; OPTIMAL DRUG DOSE; PANCREATITIS; PATIENT COMPLIANCE; PRURITUS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SUPERINFECTION; TEMPERATURE; THERAPY DELAY; THROMBOCYTOPENIA; WATER RETENTION; WEIGHT REDUCTION;

HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; RIBAVIRIN;

EID: 34248338835     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Sulkowski M, Brinkley-Laughton S, Thomas D. HCV and HIV coinfection: Prevalence, genotype distribution and severity of liver disease in an urban HIV clinic. Hepatology 2000;32:204.
2. Troisi C, Hollinger F, Hoots W, et al. A multicenter study of viral hepatitis in a U.S. hemophiliac population. Blood 1993;81:412-8.
3. Sherman K, Rouster S, Chung H, Rajicic N. HCV prevalence among patients infected with HIV: a cross-sectional analysis of the U.S adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-7.
4. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001;32:492-7.
5. Cohen M, French A, Benning L, et al. Causes of death among women with HIV infection in the era of combination antiretroviral therapy. Am J Med 2002;113:91-8.
6. Martin-Carbonero L, Soriano V, Valencia E et al. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17:1467-71.
7. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000;24:211-7.
8. Bonacini M, Louie S, Bzowej N, Wohl A. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004; 18:2039-45.
9. Thomas D, Astemborski J, Rai R, et al. The natural history of HCV infection: host, viral, and environmental factors. JAMA 2000; 284:450-6.
10. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in HIV and HCV coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-8.
11. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV coinfected patients. J Hepatol 2005; 42:615-24.
12. Nelson M, Matthews G, Brook G, Main J. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and HCV infection. HIV Med 2005;6(Suppl 2):96-106.
13. Tien P; Veterans Affairs Hepatitis C Resource Center Program; National Hepatitis C Program Office. Management and treatment of HCV infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J Gastroenterol 2005;100:2338-54.
14. Davis G, Wong B, McHutchinson J, et al. Early virologic response to treatment with PEG-IFNα-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
15. Opravil M, Torriani F, Sasadeusz J, et al. Treatment exposure and sustained virologic response in genotype 1 patients treated with PEG-IFNα-2a (40 kDa) plus ribavirin in APRICOT (AIDS PEGASYS Ribavirin International Coinfection Trial). Program and abstracts of the 45th ICAAC; December 16-19, 2005; Washington, DC [abstract V-1179].
16. Sherman K. Implications of PEG-IFN use in special populations infected with HCV. Semin Liver Dis 2003;23(Suppl 1):47-52.
17. Manns M, McHutchinson, Gordon S, et al. PEG-IFNα-2b plus ribavirin compared with IFNα-2b plus ribavirin for initial treatment of chronic hepatitis c: a randomized trial. Lancet 2001;358:958-65.
18. Fried M, Mitchell M. PEG-IFNα-2a plus ribavirin for chronic HCV infection. N Engl J Med 2002;347:975-82.
19. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. PEG-IFNα-2a plus ribavirin for chronic HCV infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
20. Carrat F, Bani-Sadr F, Pol S, et al. PEG-IFNα-2b vs. standard IFNα-2b, plus ribavirin, for chronic hepatitis C in HIV-intected patients: a randomized controlled trial. JAMA 2004;292:2839-48.
21. Laguno M, Murillas J, Blanco J, et al. PEG-IFNα-2b plus ribavirin compared with IFNα-2b plus ribavirin for the treatment of HIV/HCV coinfected patients. AIDS 2004;18:F27-36.
22. Chung R, Andersen J, Volberding P, et al. PEG-IFNα-2a plus ribavirin vs. IFNα-2a plus ribavirin for chronic HCV infection in HIV-coinfected persons. N Engl J Med 2004;351:451-9.
23. Cargnel A, Angeli E, Mainini A, et al. Open, randomized, multicenter Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV coinfected patients on HAART. Antivir Ther 2005;10:309-17.
24. Ernstoff M, Kirkwood J. Changes in the bone marrow of cancer patients treated with recombinant IFNα-2 Am J Med 1984;76:593-6.
25. Ramos-Casals M, Garcia-Carrasco M, Lopez-Medrano F, et al. Severe autoimmune cytopenias in treatment-naive HCV infection: clinical description of 35 cases. Medicine (Balt) 2003;82:87-96.
26. Levine A, Karim R, Mack W, et al. Neutropenia in HIV infection: data from the women's interagency HIV study. Arch Int Med 2006;166:405-10.
27. Schmid M, Kreil A, Jessner W, et al. Suppression of hematopoiesis during therapy of chronic hepatitis C with different IFNα mono and combination therapy regimens. Gut 2005;54:1014-20.
28. Puoti M, Babudieri S, Rezza G, et al. Use of PEG-IFN is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther 2004;9:627-30.
29. Soza A, Everhart J, Ghany M, et al. Neutropenia during combination therapy with IFNα and ribavinin for chronic hepatitis C. Hepatology 2002;36:1273-9.
30. Cooper C, Al-Bedwawi S, Lee C, et al. Rate of infectious complications during IFN-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006;42:1674-8.
31. Pegasys® (PEG-IFNα-2a) [package insert]. Nutley, NJ: Hoffmann-La Roche, Inc., 2002.
32. PEG-Intron® (PEG-IFNα-2b, recombinant) [package insert]. Kenilworth. NJ: Schering Corporation 2002.
33. Armstrong W, Kazanjian P. Use of cytokines in HIV-infected patients: colony-stimulating factors, erythropoietin, and interleukin-2. Clin Infect Dis 2001;32:766-73.
34. Golia P, Talal A, Jacobson I, et al, A preliminary study of growth factors versus dose reduction for PEG-IFNα-2b and ribavirin associated neutropenia and anemia in HIV/HCV coinfected patients. Gastroenterology 2003;124:766.
35. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV coinfection. AIDS 2004;18:1-12.
36. Moreno L, Carmen Q, Moreno A, et al. PEG-IFNα-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004;18:67-73.
37. Afdhal N, Dieterich D, Pockros P, et al. Proactive Study Group. Epoetin-α maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-11.
38. Dieterich D. Treatment of hepatitis C and anemia in HIV-infected patients. J Infect Dis 2002;185(Suppl 2):128-37.
39. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic HCV infection: role of membrane oxidative damage. Hepatology 2000,31:997-1004.
40. Kato K, Kamezaki K, Shimoda K, et al. Intracellular signal transduction of IFN on the suppression of hematopoietic progenitor cell growth. Br J Haematol 2003;123:528-35.
41. Tarumi T, Sawada K, Sato N, et al. IFNα induced apoptosis in human erythroid progenitors. Exp Haematol 1995;23:1310-8.
42. Pellicano R, Smedile A, Peyre S, et al. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologists view. Minerva Gastroenterol Dietol 2005;51:55-61.
43. Fangman J, Scadden D. Anemia in HIV-infected adults: epidemiology, pathogenesis, and clinical management. Curr Hematol Rep 2005;4:95-102.
44. Lindhal K, Schvarcz R, Bruchfeld A, et al. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anemia. J Viral Hepatol 2004;11:84-7.
45. Rendon A, Nunez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/ HCV-coinfected patients. J Acquir Immune Defic Syndr 2005;39:401-5.
46. Sulkowski M, Dieterich D, Bini E, et al. Epoetin-α once weekly improves anemia in HIV/HCV-coinfected patients treated patients treated with IFN/ribavirin: a randomized controlled trial J Acquir Immune Defic Syndr 2005;39:504-6.
47. Trivedi HS, Trivedi M. Subnormal rise of erythropoietin in patients receiving IFN and ribavirin combination therapy for hepatitis C. J Clin Gastroenterol 2004;38:595-8.
48. Wu G, Larson G, Walzer H, et al. Phosphorylation of ribavirin and Viramidine by adenosine-kinase and cytosolic 5′-nucleotidase II: implication for ribavirin metabolism in erythrocytes. J Agents Chemother 2005;49:2164-71.
49. Gish G. Treating HCV with ribavirin analogs and ribavirin-like molecules. J Agents Chemother 2006;57:8-13.
50. Benhamou Y, Pockros P, Rodriguez-Torres M, et al. The safety and efficacy of Viramidine® plus PEG-IFNα-2b versus ribavirin plus PEG-IFNα-2b in therapy-naive patients infected with HCV: phase III results. J Hapatol 2006;44(Suppl 2):273.
51. Peck-Radosavljevic M, Wichlas M, Pidlich J, et al. Blunted thrombopoietin response to IFNα induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998;28:1424-9.
52. Garcia-Suarez J, Burgaleta Chernanz N, et al. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant IFNα-2b therapy. Br J Haematol 2000;110:98-103.
53. Rustgi V, Lee P, Finnegan S, et al. Safety and efficacy of recombinant human IL-11 (Oprevlekin) in combination with IFN/ribavirin in hepatitis C patients with thrombocytopenia. Hepatology 2002;36:361.
54. Okuda M, Li K, Berd M. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by HCV core protein. Gastroenterology 2002;122:366-75.
55. De Maria N, Cantoni A, Fagioli S. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radical Biology Med 1996;21:291-5.
56. Hayashi N, Mita E. FAS system and apoptosis in viral hepatitis. J Gastroenterol Hepatol 1997;12.223-6.
57. Cotè H, Brumme Z, Craib K, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-20.
58. De Mendoza C, Soriano V. The role of HCV in mitochondrial DNA damage in HIV/HCV-coinfected individuals. Antivir Ther 2005; 10(Suppl 2):M109-15.
59. Garcia Benayas T, Blanco F, Soriano V. Weight loss in HIV-infected patients N Engl J Med 2002;347:1287-8.
60. De Mendoza C, Sanchez-Conde M, Timmermans E, et al. Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with PEG-IFN plus ribavirin. Antivir Ther 2005;10:557-61.
61. Balzarini J, Lee C, Herdewijn P, et al. Mechanism of the potentiating effect of ribavirin on the activity of 2′-3′-dideoxyinosine against HI-SEE. J of Biological Chemistry 1991;266:21509-14.
62. Laguno M, Milinkovic A, de Lazzari E, et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther 2005;10:423-9.
63. Mauss S, Valenti W, De Pamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during IFN-based therapy. AIDS 2004;18:F21-5.
64. Fleming A, Christiansen D, Nunes D, et al. Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection. Clin Infect Dis 2004;38:572-8.
65. Breitstein F, Montessori V, Chan K, et al. Quality of life, depression and fatigue among persons coinfected with HIV and hepatitis C: outcomes from a population-based cohort. AIDS Care 2005;17:505-15.
66. Dieperink E, Willwmbring M, Ho S, et al. Neuropsychiatric symptoms associated with hepatitis C and IFNα: a review. Am J Psychiatry 2000;157:867-76.
67. Loftis J, Hauser P. The phenomenology and treatment of IFN-induced depression. J Affect Disord 2004;82:175-90.
68. Dan A, Martin L, Crone C, et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006;44:491-8.
69. Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, IFNα and depression. Hepatology 2000;31:1207-11.
70. Raison D, Borisov A, Broadwelll S, et al. Depression during PEG-IFNα plus ribavirin: prevalence and prediction. Am J Psychiatry 2005;66:41-8.
71. Gleason O, Yates W, Isbell M, et al. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002;63194-8.
72. Schramm T, Lawford B, Macdonald G, Cooksley W. Serafraline treatment of IFNα-inducad depressive disorder. Med J Aust 2000; 173:359-61.
73. Gutierrez M, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between ascitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003; 25:1200-10.
74. Yu B, Chen G, He N, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos 2003;31:1255-9.
75. Laguno M, Blanch J, Murillas J, et al. Depressive symptoms after initiation of IFN therapy in HIV-infectad patients with chronic hepatitis C. Antivir Ther 2006;9:905-9.